Investigation (in vivo and in vitro) of booster dose vaccine requirement for long-term protection against hepatitis b virus infection

Basit Öğe Kaydı
dc.contributor.authorSaygun, Onur
dc.contributor.authorEyigün, Can Polat
dc.contributor.authorAvcı, İsmail Yaşar
dc.contributor.authorKısa, Üçler
dc.contributor.authorPahsa, Alaaddin
dc.date.accessioned2021-01-14T18:16:22Z
dc.date.available2021-01-14T18:16:22Z
dc.date.issued2009
dc.description.abstractAim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P < 0.05). In all subjects in the study group, anti-HBs response (?10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P < 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.en_US
dc.description.abstractAim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P &lt; 0.05). In all subjects in the study group, anti-HBs response (&amp;#8805;10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P &lt; 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.en_US
dc.identifier.citationSaygun O., Eyigün C. P., Avcı İ. Y., Kısa Ü., Pahsa A. (2009). Investigation (in vivo and in vitro) of booster dose vaccine requirement for long-term protection against hepatitis b virus infection. Turkish Journal of Medical Sciences, 39(2), 173 - 177.en_US
dc.identifier.endpage177en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-65249168122
dc.identifier.scopusqualityQ1
dc.identifier.startpage173en_US
dc.identifier.trdizinid90370
dc.identifier.urihttps://app.trdizin.gov.tr/makale/T1RBek56QXc
dc.identifier.urihttps://hdl.handle.net/20.500.12587/13144
dc.identifier.volume39en_US
dc.identifier.wosWOS:000265263900003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCerrahien_US
dc.titleInvestigation (in vivo and in vitro) of booster dose vaccine requirement for long-term protection against hepatitis b virus infectionen_US
dc.title.alternativeHepatit B virüsüne karşı aşılamada uzun süreli korunma için booster doz gerekliliğinin (in vivo ve in vitro) araştırılmasıen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
0e3f5377-478a-48ef-8403-3ca1ebccccca.pdf
Boyut:
76.35 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WOS İndeksli Yayınlar Koleksiyonu